Month: May 2021

Disposable Medical Gloves Market Size 2021 | To Reach USD 11.52 Billion by 2027; Rising Demand for Gloves to Maintain Personal Hygiene to Bolster Market Growth: Fortune Business Insights™

Written by Customer Service on May 5, 2021. Posted in Mergers And Acquisitions.

Top Players Covered in the Disposable Medical Gloves Market Research Report Are Kossan Rubber Industries Bhd (Selangor, Malaysia), Halyard Health (Georgia, United States), Ansell Ltd (Richmond, Australia), KANAM LATEX INDUSTRIES PVT LTD (Kerala, India), Top Glove Corporation Bhd (Shah Alam, Malaysia), Elite Surgical, Hartalega Holdings Bhd (Kuala Lumpur, Malaysia), Dynarex Corporation (New York, United States), Mölnlycke Health Care AB (Gothenburg, Sweden), Cardinal Health (Ohio, United States) and other key market players. Pune, India, May 05, 2021 (GLOBE NEWSWIRE) — Disposable Medical Gloves Market Size| 2021 Covid-19 Impact On Automotive Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional Forecast To 2026 is latest study published by Fortune...

Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases

Written by Customer Service on May 5, 2021. Posted in Mergers And Acquisitions.

– Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline – Lead pipeline product Oleogel-S10*(Filsuvez®) under regulatory review in the US and EU – Deal expected to pave a path to a combined potential $1BN peak revenue for Amryt – The acquisition is expected to deliver estimated annual cost synergies of approximately $50M and be revenue and EBITDA accretive and cash generative in the first full calendar year of combined operations and substantially accretive thereafter – MYCAPSSA® is the first and only oral somatostatin analog (“SSA”) approved for appropriate patients with acromegaly in a global market estimated at approximately $800M with the potential to expand into the neuroendocrine...

Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases

Written by Customer Service on May 5, 2021. Posted in Mergers And Acquisitions.

Hemostats Market Anticipated to Reach USD 5.44 Billion with 6.3% CAGR by 2027; Rising Number of Chronic Ailments to Add Impetus to Market | Fortune Business Insights™

Written by Customer Service on May 5, 2021. Posted in Mergers And Acquisitions.

Top Players Covered in the Hemostats Market Research Report are Baxter, Integra LifeSciences Corporation, Stryker, CryoLife, Inc., Biom’up, BD (Becton, Dickinson and Company), Medtronic, Johnson & Johnson Services, Inc., Pfizer Inc. and other key market players Pune, India, May 05, 2021 (GLOBE NEWSWIRE) — The global “hemostats market” size is expected to reach USD 5.54 billion by 2027, while exhibiting a CAGR of 6.3% between 2020 and 2027. This is ascribable to factors such as increasing prevalence of chronic disease and growing demand for technologically advanced products. Fortune Business Insights, publish this information in its latest report, titled “Hemostats Market Size, Share & Covid-19 Impact Analysis, By Product (Active Hemostats, Passive Hemostats, Combination Hemostats, and Others), By Application (Trauma,...

Emerging Markets Report: Rapid and Real Time

Written by Customer Service on May 5, 2021. Posted in Public Companies.

An Emerging Markets Sponsored Commentary ORLANDO, Fla., May 05, 2021 (GLOBE NEWSWIRE) — Allow us to introduce Relay Medical Corp. (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2). The Company is a technology innovation company headquartered in Toronto, Ontario, with a team of Canadian experts focused on the development of novel technologies in the diagnostics, AI data science sectors, and IoT cybersecurity sectors. Relay Medical announced on April 14, 2021 that together in conjunction with Fio Corporation and Fio’s joint venture company, Fionet Rapid Response Group, an agreement with LifeLabs was completed, to deploy the Fionet Platform for COVID-19 rapid testing and real-time tracking across Canada, and will be used to launch the Company’s platform to support COVID-19 testing at Canada’s largest international airport Pearson International. For...

Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt

Written by Customer Service on May 5, 2021. Posted in Mergers And Acquisitions.

Announced agreement to merge with Amryt Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage development pipeline Q1 2021 Net Product Revenues of $1.9M, a 100% increase over Q4 2020 Achieved payor coverage of MYCAPSSA for over 185 million lives Submitted an Investigational New Drug (IND) application for the study of MYCAPSSA in patients with carcinoid syndrome associated with Neuroendocrine Tumors (NET) NEEDHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its initiation of a phased U.S. commercial...

Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Written by Customer Service on May 5, 2021. Posted in Public Companies.

MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Wednesday, May 12, 2021, at 8:45 a.m. ET. A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event. About Galera Therapeutics Galera Therapeutics, Inc. is a clinical-stage...

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer

Written by Customer Service on May 5, 2021. Posted in Public Companies.

Mark ShearmanEditas Medicine announced that it named Mark Shearman as the Company’s Executive Vice President and Chief Scientific Officer.CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development for the Company’s pipeline of experimental medicines. “We are delighted to have Mark join our team in June. Mark has an outstanding track record of drug discovery and development and leading high performing teams. Specifically, during his career, he has led discovery programs across multiple modalities, including ophthalmology,...

Alico, Inc. Announces Strategic Actions to Increase Long-term Shareholder Returns

Written by Customer Service on May 5, 2021. Posted in Dividend Reports And Estimates.

FORT MYERS, Fla., May 05, 2021 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announces significant enhancements that are expected to generate greater returns for our shareholders. In November 2017, the Company announced the Alico 2.0 Modernization Program, which improved the operational efficiencies and optimized asset returns of Alico. Highlights included:Transformed three legacy citrus businesses into a single optimized enterprise now known as Alico Citrus. Reduced operating and G&A costs by 19% without negative impact on business operations. Planted approximately 1.5 million trees over the past four years, which are expected to steadily increase production beginning in fiscal year 2022. Expanded owned citrus operations to 49,000 acres, up from 45,000 acres. Divested more than $105 million...

Immune Health Supplements Market Size 2021 | Is Projected to Reach USD 31.50 Billion by 2028, Exhibiting a CAGR of 6.6%

Written by Customer Service on May 5, 2021. Posted in Mergers And Acquisitions.

Key Prominent Players Covered in the Immune Health Supplements Market Research Report Are Herbalife Nutrition (California, United States) ,Nutramax Laboratories (Maryland, United States) ,BioGaia (Stockholm, Sweden) ,Blackmores Limited (New South Wales, Australia) ,Glanbia, Plc (Kilkenny, Ireland) , Royal DSM (Heerlen, Netherlands) , Alticor Inc. (Amway) (Michigan, United States) ,USANA Health Sciences (Utah, United States) , Bayer AG (Leverkusen, Germany) , NOW Foods (Illinois, United States) , Pfizer (New York, United States) ,Other key market players Pune, India, May 05, 2021 (GLOBE NEWSWIRE) — The global immune health supplements market is set to gain momentum from the rising awareness of clean label products infused with minimally processed and natural ingredients. In May 2020, for instance, Ancient Nutrition introduced a...

Month: May 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals